Search

Your search keyword '"Kwak, Lucia"' showing total 211 results
Start Over Author "Kwak, Lucia"
211 results on '"Kwak, Lucia"'

2. Supplemental Figure 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

3. Data from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

4. Supplemental Table 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

5. Supplemental Figure 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

6. Supplemental Table 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

7. Supplemental Figure 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

8. Supplemental Table 1 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

9. Supplemental Figure 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

10. Supplemental Figure 8 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

11. Supplemental Table 6 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

12. Supplemental Figure 7 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

13. Supplemental Table 2 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

14. Supplementary File 3 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

15. Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

16. Supplemental Table 4 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, primary, Cheung, Alexander, primary, Allaire, Kathryn M., primary, Marquez, Jaqueline, primary, Yang, David D., primary, Tripathi, Abhishek, primary, Kilar, Jacqueline M., primary, Flynn, Meredith, primary, Maynard, Brianna, primary, Reichel, Rebecca, primary, Pace, Amanda F., primary, Chen, Brandon K., primary, Van Allen, Eliezer M., primary, Kilbridge, Kerry, primary, Wei, Xiao X., primary, McGregor, Bradley A., primary, Pomerantz, Mark M., primary, Bhatt, Rupal S., primary, Sweeney, Christopher J., primary, Bubley, Glenn J., primary, Jacene, Heather A., primary, Taplin, Mary-Ellen, primary, Huang, Franklin W., primary, Harshman, Lauren C., primary, and Fong, Lawrence, primary

Published
2024
Full Text
View/download PDF

18. Characterizing genomic alterations in patients with metastatic urothelial carcinoma (mUC) treated with enfortumab-vedotin (EV) with a focus on 1q23.3.

Author

Saliby, Renee Maria, primary, Semaan, Karl, additional, Epstein, Ilana B., additional, Liria, Sonsoles, additional, Dall, Christopher, additional, Saad, Eddy, additional, Eid, Marc, additional, Canniff, John, additional, Kwak, Lucia, additional, Berg, Stephanie A., additional, Mantia, Charlene, additional, McGregor, Bradley Alexander, additional, Braun, David A., additional, CHOUEIRI, Toni K., additional, and Bellmunt, Joaquim, additional

Published
2024
Full Text
View/download PDF

19. Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials.

Author

Ravi, Praful, primary, Kwak, Lucia, additional, Acosta, Andrew, additional, Rastogi, Saahil, additional, Xie, Wanling, additional, Einstein, David Johnson, additional, Chang, Peter K., additional, Wagner, Andrew, additional, McKay, Rana R., additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2024
Full Text
View/download PDF

23. Kidney function, bone-mineral metabolism markers, and future risk of peripheral artery disease

Author

Yang, Chao, Kwak, Lucia, Ballew, Shoshana H, Garimella, Pranav S, Jaar, Bernard G, Folsom, Aaron R, Heiss, Gerardo, Selvin, Elizabeth, Lutsey, Pamela L, Coresh, Josef, and Matsushita, Kunihiro

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, Cardiovascular, Clinical Research, Prevention, Atherosclerosis, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Renal and urogenital, Biomarkers, Body Mass Index, Bone Density, Bone and Bones, Calcium, Creatinine, Cystatin C, Female, Fibroblast Growth Factor-23, Fibroblast Growth Factors, Follow-Up Studies, Glomerular Filtration Rate, Hospitalization, Humans, Incidence, Kidney, Kidney Function Tests, Male, Middle Aged, Parathyroid Hormone, Peripheral Arterial Disease, Phosphorus, Proportional Hazards Models, Prospective Studies, Risk Factors, beta 2-Microglobulin, Peripheral artery disease, Kidney markers, Bone-mineral metabolism markers, Prospective cohort study, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

Background and aimsReduced kidney function is a risk factor for lower-extremity peripheral artery disease (PAD). However, the associations of novel filtration markers with PAD are yet to be quantified. Moreover, little is known on whether bone-mineral metabolism (BMM) markers are related to incident PAD beyond kidney function.MethodsUsing data from 12,472 participants at baseline (1990-1992) of the Atherosclerosis Risk in Communities (ARIC) study, we comprehensively quantified the associations of kidney related markers with incident PAD (defined as hospitalizations with diagnosis of lower-extremity atherosclerosis, revascularization, or amputation). Kidney related markers of interest included estimated glomerular filtration rate (eGFR) (based on creatinine, cystatin C, and both), cystatin C, beta-2 microglobulin (B2M), and BMM markers (serum fibroblast growth factor 23, parathyroid hormone, calcium, and phosphorus).ResultsDuring a median follow-up of 21 years, 471 participants developed incident PAD. Low eGFR was significantly associated with future PAD risk, with slightly stronger relationship when cystatin C was used (adjusted hazard ratio [HR] 6.3-8.3 for eGFR

Published
2017

24. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

Author

Matsushita, Kunihiro, Ballew, Shoshana H, Coresh, Josef, Arima, Hisatomi, Ärnlöv, Johan, Cirillo, Massimo, Ebert, Natalie, Hiramoto, Jade S, Kimm, Heejin, Shlipak, Michael G, Visseren, Frank LJ, Gansevoort, Ron T, Kovesdy, Csaba P, Shalev, Varda, Woodward, Mark, Kronenberg, Florian, Chalmers, John, Perkovic, Vlado, Grams, Morgan E, Sang, Yingying, Schaeffner, Elke, Martus, Peter, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Heine, Gunnar, Seiler, Sarah, Zawada, Adam, Emrich, Insa, Sarnak, Mark, Katz, Ronit, Brenner, Hermann, Schöttker, Ben, Rothenbacher, Dietrich, Saum, Kai-Uwe, Köttgen, Anna, Schneider, Markus, Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Black, Corri, Marks, Angharad, Prescott, Gordon, Clark, Laura, Fluck, Nick, Jee, Sun Ha, Mok, Yejin, Chodick, Gabriel, Wetzels, Jack FM, Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Peralta, Carmen, Hiromoto, Jade, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Kenealy, Timothy, Elley, C Raina, Collins, John F, Drury, Paul L, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kalantar-Zadeh, Kamyar, Carrero, Juan J, Gasparini, Alessandro, Qureshi, Abdul Rashid, Barany, Peter, Algra, Ale, van der Graaf, Yolanda, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Lannfelt, Lars, Larsson, Anders, Hallan, Stein, Levey, Andrew S, Chen, Jingsha, and Kwak, Lucia

Subjects
Clinical Research, Kidney Disease, Prevention, Renal and urogenital, Good Health and Well Being, Adult, Aged, Albuminuria, Creatinine, Databases, Factual, Female, Glomerular Filtration Rate, Humans, Incidence, Male, Middle Aged, Peripheral Arterial Disease, Renal Insufficiency, Chronic, Risk Factors, Chronic Kidney Disease Prognosis Consortium, Medical Biochemistry and Metabolomics, Clinical Sciences, Public Health and Health Services
Abstract

BackgroundSome evidence suggests that chronic kidney disease is a risk factor for lower-extremity peripheral artery disease. We aimed to quantify the independent and joint associations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and albuminuria) with the incidence of peripheral artery disease.MethodsIn this collaborative meta-analysis of international cohorts included in the Chronic Kidney Disease Prognosis Consortium (baseline measurements obtained between 1972 and 2014) with baseline measurements of eGFR and albuminuria, at least 1000 participants (this criterion not applied to cohorts exclusively enrolling patients with chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult participants without peripheral artery disease at baseline at the individual patient level with Cox proportional hazards models to quantify associations of creatinine-based eGFR, urine albumin-to-creatinine ratio (ACR), and dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation). We assessed discrimination improvement through c-statistics.FindingsWe analysed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts. 18 261 cases of peripheral artery disease were recorded during follow-up across cohorts (median follow-up was 7·4 years [IQR 5·7-8·9], range 2·0-15·8 years across cohorts). Both chronic kidney disease measures were independently associated with the incidence of peripheral artery disease. Compared with an eGFR of 95 mL/min per 1·73 m2, adjusted hazard ratios (HRs) for incident study-specific peripheral artery disease was 1·22 (95% CI 1·14-1·30) at an eGFR of 45 mL/min per 1·73 m2 and 2·06 (1·70-2·48) at an eGFR of 15 mL/min per 1·73 m2. Compared with an ACR of 5 mg/g, the adjusted HR for incident study-specific peripheral artery disease was 1·50 (1·41-1·59) at an ACR of 30 mg/g and 2·28 (2·12-2·44) at an ACR of 300 mg/g. The adjusted HR at an ACR of 300 mg/g versus 5 mg/g was 3·68 (95% CI 3·00-4·52) for leg amputation. eGFR and albuminuria contributed multiplicatively (eg, adjusted HR 5·76 [4·90-6·77] for incident peripheral artery disease and 10·61 [5·70-19·77] for amputation in eGFR

Published
2017

26. Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Author

Choudhury, Atish D., primary, Kwak, Lucia, additional, Cheung, Alexander, additional, Allaire, Kathryn M., additional, Marquez, Jaqueline, additional, Yang, David D., additional, Tripathi, Abhishek, additional, Kilar, Jacqueline M., additional, Flynn, Meredith, additional, Maynard, Brianna, additional, Reichel, Rebecca, additional, Pace, Amanda F., additional, Chen, Brandon K., additional, Van Allen, Eliezer M., additional, Kilbridge, Kerry, additional, Wei, Xiao X., additional, McGregor, Bradley A., additional, Pomerantz, Mark M., additional, Bhatt, Rupal S., additional, Sweeney, Christopher J., additional, Bubley, Glenn J., additional, Jacene, Heather A., additional, Taplin, Mary-Ellen, additional, Huang, Franklin W., additional, Harshman, Lauren C., additional, and Fong, Lawrence, additional

Published
2024
Full Text
View/download PDF

27. Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials

Author

Kwak, Lucia, primary, Ravi, Praful, additional, Armstrong, John G., additional, Beckendorf, Veronique, additional, Chin, Joseph L., additional, D'Amico, Anthony V., additional, Dearnaley, David P., additional, Di Stasi, Savino M., additional, Gillessen, Silke, additional, Lukka, Himanshu, additional, Mottet, Nicolas, additional, Pommier, Pascal, additional, Seiferheld, Wendy, additional, Sydes, Matthew R., additional, Tombal, Bertrand, additional, Zapatero, Almudena, additional, Regan, Meredith M., additional, Xie, Wanling, additional, and Sweeney, Christopher J., additional

Published
2024
Full Text
View/download PDF

28. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes

Author

Nassar, Amin H, primary, El Zarif, Talal, additional, Khalid, Ahmed Bilal, additional, Rahme, Serena, additional, Zhong, Caiwei, additional, Kwak, Lucia, additional, Salame, Marita, additional, Farhat, Elias Bou, additional, Freeman, Dory, additional, El-Am, Edward, additional, Ravishankar, Arjun, additional, Ahmad, Bachar, additional, Nana, Frank Aboubakar, additional, Kaldas, David, additional, Naqash, Abdul Rafeh, additional, Sharon, Elad, additional, LeBoeuf, Nicole R, additional, Cortellini, Alessio, additional, Malgeri, Andrea, additional, Gupta, Shruti, additional, Al-Hader, Ahmad, additional, Sparks, Jeffrey A, additional, Linnoila, Jenny, additional, Hamnvik, Ole-Petter R, additional, Mouhieddine, Tarek H, additional, Marron, Thomas, additional, Parikh, Kaushal, additional, McKay, Rana R, additional, Dilling, Thomas, additional, Choueiri, Toni K, additional, Adib, Elio, additional, Najem, Elie, additional, Kim, So Yeon, additional, and Sonpavde, Guru, additional

Published
2024
Full Text
View/download PDF

29. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Author

Appel, Lawrence J, Greene, Tom, Chen, Teresa K, Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Nally, Joseph, Navaneethan, Sankar D, Schold, Jesse D, Weldegiorgis, Misghina, Herrington, William G, Smith, Margaret, Hsu, C Yenchih, Hwang, Shih-Jen, Chang, Alex R, Kirchner, H. Lester, Green, Jamie A, Ho, Kevin, Marks, Angharad, Prescott, Gordon, Clark, Laura E, Fluck, Nick, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Van Zuilen, Arjan, Van den Brand, Jan A, Sarnak, Mark J, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen G, Nadukuru, Rajiv, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Froissart, Marc, Kenealy, Timothy, Elley, Raina C, Collins, John F, Drury, Paul L, Cuddeback, John K, Ciemins, Elizabeth L, Stempniewicz, Rich, Nelson, Robert G, Knowler, William C, Bakker, Stephen J, Major, Rupert W, Medcalf, James F, Shepherd, David, Barrett-Connor, Elizabeth, Bergstrom, Jaclyn, Ix, Joachim H, Molnar, Miklos Z, Sumida, Keiichi, de Zeeuw, Dick, Brenner, Barry, Qureshi, Abdul R, Elinder, Carl-Gustaf, Runesson, Bjorn, Evans, Marie, Segelmark, Marten, Stendahl, Maria, Schön, Staffan, Naimark, David M, Tangri, Navdeep, Sud, Maneesh, Hirayama, Atsushi, Ichikawa, Kazunobu, Bilo, Henk JG, Landman, Gijs WD, Van Hateren, Kornelis JJ, Kleefstra, Nanne, Hallan, Stein I, Ballew, Shoshana H, Chen, Jingsha, Kwak, Lucia, Surapaneni, Aditya, Parving, Hans-Henrik, Rodby, Roger A., Rohde, Richard D, Lewis, Julia B, Lewis, Edmund, Perrone, Ronald D, Abebe, Kaleab Z, Hou, Fan F, Xie, Di, Hunsicker, Lawrence G, Imai, Enyu, Kobayashi, Fumiaki, Makino, Hirofumi, Ito, Sadayoshi, Remuzzi, Giuseppe, Ruggenenti, Piero, Eckardt, Kai-Uwe, Gudmundsdottir, Hrefna, Maciulaitis, Romaldas, Manley, Tom, Smith, Kimberly, Stockbridge, Norman, Thompson, Aliza, Vetter, Thorsten, Willis, Kerry, Zhang, Luxia, Coresh, Josef, Heerspink, Hiddo J L, Sang, Yingying, Matsushita, Kunihiro, Arnlov, Johan, Astor, Brad C, Black, Corri, Brunskill, Nigel J, Carrero, Juan-Jesus, Feldman, Harold I, Fox, Caroline S, Inker, Lesley A, Ishani, Areef, Jassal, Simerjot, Konta, Tsuneo, Polkinghorne, Kevan, Romundstad, Solfrid, Solbu, Marit D, Stempniewicz, Nikita, Stengel, Benedicte, Tonelli, Marcello, Umesawa, Mitsumasa, Waikar, Sushrut S, Wen, Chi-Pang, Wetzels, Jack F M, Woodward, Mark, Grams, Morgan E, Kovesdy, Csaba P, Levey, Andrew S, and Gansevoort, Ron T

Published
2019
Full Text
View/download PDF

30. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

Author

Astor, Brad, Appel, Larry, Greene, Tom, Chen, Teresa, Chalmers, John, Woodward, Mark, Arima, Hisatomi, Perkovic, Vlado, Yatsuya, Hiroshi, Tamakoshi, Koji, Li, Yuanying, Hirakawa, Yoshihisa, Coresh, Josef, Matsushita, Kunihiro, Grams, Morgan, Sang, Yingying, Polkinghorne, Kevan, Chadban, Steven, Atkins, Robert, Levin, Adeera, Djurdjev, Ognjenka, Zhang, Luxia, Liu, Lisheng, Zhao, Minghui, Wang, Fang, Wang, Jinwei, Schaeffner, Elke, Ebert, Natalie, Martus, Peter, Tang, Mila, Heine, Gunnar, Emrich, Insa, Seiler, Sarah, Zawada, Adam, Nally, Joseph, Navaneethan, Sankar, Schold, Jesse, Shlipak, Michael, Sarnak, Mark, Katz, Ronit, Hiramoto, Jade, Iso, Hiroyasu, Yamagishi, Kazumasa, Umesawa, Mitsumasa, Muraki, Isao, Fukagawa, Masafumi, Maruyama, Shoichi, Hamano, Takayuki, Hasegawa, Takeshi, Fujii, Naohiko, Wheeler, David, Emberson, John, Townend, John, Landray, Martin, Brenner, Hermann, Schöttker, Ben, Saum, Kai-Uwe, Rothenbacher, Dietrich, Fox, Caroline, Hwang, Shih-Jen, Köttgen, Anna, Kronenberg, Florian, Schneider, Markus P., Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R., Ho, Kevin, Ito, Sadayoshi, Miyazaki, Mariko, Nakayama, Masaaki, Yamada, Gen, Cirillo, Massimo, Irie, Fujiko, Sairenchi, Toshimi, Ishikawa, Shizukiyo, Yano, Yuichiro, Kotani, Kazuhiko, Nakamura, Takeshi, Jee, Sun Ha, Kimm, Heejin, Mok, Yejin, Chodick, Gabriel, Shalev, Varda, Wetzels, Jack F.M., Blankestijn, Peter J., van Zuilen, Arjan D., van den Brand, Jan, Inker, Lesley, Peralta, Carmen, Kollerits, Barbara, Ritz, Eberhard, Nitsch, Dorothea, Roderick, Paul, Fletcher, Astrid, Bottinger, Erwin, Nadkarni, Girish N., Ellis, Stephen B., Nadukuru, Rajiv, Ueshima, Hirotsugu, Okayama, Akira, Miura, Katsuyuki, Tanaka, Sachiko, Okamura, Tomonori, Kadota, Aya, Kenealy, Timothy, Elley, C Raina, Collins, John F., Drury, Paul L., Ohkubo, Takayoshi, Asayama, Kei, Metoki, Hirohito, Kikuya, Masahiro, Nelson, Robert G., Knowler, William C., Gansevoort, Ron T., Bakker, Stephan JL., Hak, Eelco, Heerspink, Hiddo J.L., Brunskill, Nigel, Major, Rupert, Shepherd, David, Medcalf, James, Jassal, Simerjot K., Bergstrom, Jaclyn, Ix, Joachim H., Barrett-Connor, Elizabeth, Kovesdy, Csaba, Kalantar-Zadeh, Kamyar, Sumida, Keiichi, Gutierrez, Orlando M., Muntner, Paul, Warnock, David, McClellan, William, de Zeeuw, Dick, Brenner, Barry, Sedaghat, Sanaz, Ikram, M Arfan, Hoorn, Ewout J., Dehghan, Abbas, Carrero, Juan J., Gasparini, Alessandro, Wettermark, Björn, Elinder, Carl-Gustaf, Wong, Tien Yin, Sabanayagam, Charumathi, Cheng, Ching-Yu, Visseren, Frank L.J., Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Wen, Chi-Pang, Tsao, Chwen-Keng, Tsai, Min-Kugng, Chen, Chien-Hua, Konta, Tsuneo, Hirayama, Atsushi, Ichikawa, Kazunobu, Lannfelt, Lars, Larsson, Anders, Ärnlöv, Johan, Bilo, Henk J.G., Landman, Gijs W.D., van Hateren, Kornelis J.J., Kleefstra, Nanne, Coresh (Chair, Josef, Grams, Morgan E., Hallan, Stein, Kovesdy, Csaba P., Levey, Andrew S., Ballew, Shoshana H., Chen, Jingsha, Kwak, Lucia, Surapaneni, Aditya, Inker, Lesley A., Heine, Gunnar H., Landray, Martin J., Peralta, Carmen A., Shlipak, Michael G., and Hallan, Stein I.

Published
2019
Full Text
View/download PDF

36. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data

Author

Chalmers, John, Arima, Hisatomi, Perkovic, Vlado, Grams, Morgan E., Sang, Yingying, Schaeffner, Elke, Martus, Peter, Levin, Adeera, Djurdjev, Ognjenka, Tang, Mila, Heine, Gunnar, Seiler, Sarah, Zawada, Adam, Emrich, Insa, Sarnak, Mark, Katz, Ronit, Brenner, Hermann, Schöttker, Ben, Rothenbacher, Dietrich, Saum, Kai-Uwe, Köttgen, Anna, Schneider, Markus, Eckardt, Kai-Uwe, Green, Jamie, Kirchner, H Lester, Chang, Alex R, Black, Corri, Marks, Angharad, Prescott, Gordon, Clark, Laura, Fluck, Nick, Jee, Sun Ha, Mok, Yejin, Chodick, Gabriel, Shalev, Varda, Wetzels, Jack F.M., Blankestijn, Peter J, van Zuilen, Arjan D, Bots, M, Peralta, Carmen, Hiromoto, Jade, Bottinger, Erwin, Nadkarni, Girish N, Ellis, Stephen B, Nadukuru, Rajiv, Kenealy, Timothy, Elley, C Raina, Collins, John F, Drury, Paul L, Bakker, Stephan JL, Heerspink, Hiddo J Lambers, Jassal, Simerjot K, Bergstrom, Jaclyn, Ix, Joachim H, Barrett-Connor, Elizabeth, Kalantar-Zadeh, Kamyar, Carrero, Juan J, Gasparini, Alessandro, Qureshi, Abdul Rashid, Barany, Peter, Algra, Ale, van der Graaf, Yolanda, Evans, Marie, Segelmark, Mårten, Stendahl, Maria, Schön, Staffan, Tangri, Navdeep, Sud, Maneesh, Naimark, David, Lannfelt, Lars, Larsson, Anders, Hallan, Stein, Levey, Andrew S, Chen, Jingsha, Kwak, Lucia, Matsushita, Kunihiro, Ballew, Shoshana H, Coresh, Josef, Ärnlöv, Johan, Cirillo, Massimo, Ebert, Natalie, Hiramoto, Jade S, Kimm, Heejin, Shlipak, Michael G, Visseren, Frank L J, Gansevoort, Ron T, Kovesdy, Csaba P, Woodward, Mark, and Kronenberg, Florian

Published
2017
Full Text
View/download PDF

39. Supplementary Data from Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance

Author

McKay, Rana R., primary, Kwak, Lucia, primary, Crowdis, Jett P., primary, Sperger, Jamie M., primary, Zhao, Shuang G., primary, Xie, Wanling, primary, Werner, Lillian, primary, Lis, Rosina T., primary, Zhang, Zhenwei, primary, Wei, Xiao X., primary, Lang, Joshua M., primary, Van Allen, Eliezer M., primary, Bhatt, Rupal S., primary, Yu, Evan Y., primary, Nelson, Peter S., primary, Bubley, Glenn J., primary, Montgomery, R. Bruce, primary, and Taplin, Mary-Ellen, primary

Published
2023
Full Text
View/download PDF

41. Obesity, Galectin‐3, and Incident Heart Failure: The ARIC Study

Author

Florido, Roberta, primary, Kwak, Lucia, additional, Echouffo‐Tcheugui, Justin B., additional, Zhang, Sui, additional, Michos, Erin D., additional, Nambi, Vijay, additional, Goldberg, Ronald B., additional, Hoogeveen, Ron C., additional, Lazo, Mariana, additional, Gerstenblith, Gary, additional, Post, Wendy S., additional, Blumenthal, Roger S., additional, Coresh, Josef, additional, Folsom, Aaron R., additional, Selvin, Elizabeth, additional, Ballantyne, Christie, additional, and Ndumele, Chiadi E., additional

Published
2022
Full Text
View/download PDF

42. Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Author

McGregor, Bradley Alexander, primary, Kwak, Lucia, additional, Mantia, Charlene, additional, Ravi, Arvind, additional, Berchuck, Jacob E, additional, Ravi, Praful, additional, Xu, Wenxin, additional, Tuff, Martha, additional, Bellmunt, Joaquim, additional, Gao, Xin, additional, Sunkara, Rajitha, additional, and Sonpavde, Guru P., additional

Published
2022
Full Text
View/download PDF

43. A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and CDK12-loss metastatic castration-resistant prostate cancer (mCRPC).

Author

Rao, Arpit, primary, Kwak, Lucia, additional, Reimers, Melissa Andrea, additional, Reichert, Zachery R, additional, Thyagarajan, Bharat, additional, Fernandez, Kaylah, additional, Bretta, Katherine, additional, Pfaff, Kathleen L., additional, Rodig, Scott J., additional, Alva, Ajjai Shivaram, additional, Shapiro, Geoffrey, additional, Ryan, Charles J., additional, and Choudhury, Atish Dipankar, additional

Published
2022
Full Text
View/download PDF

44. Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study

Author

Hamo, Carine E., primary, Kwak, Lucia, additional, Wang, Dan, additional, Florido, Roberta, additional, Echouffo‐Tcheugui, Justin B., additional, Blumenthal, Roger S., additional, Loehr, Laura, additional, Matsushita, Kunihiro, additional, Nambi, Vijay, additional, Ballantyne, Christie M., additional, Selvin, Elizabeth, additional, Folsom, Aaron R., additional, Heiss, Gerardo, additional, Coresh, Josef, additional, and Ndumele, Chiadi E., additional

Published
2022
Full Text
View/download PDF

45. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer

Author

Sperger, Jamie M., primary, Emamekhoo, Hamid, additional, McKay, Rana R., additional, Stahlfeld, Charlotte N., additional, Singh, Anupama, additional, Chen, Xinyi E., additional, Kwak, Lucia, additional, Gilsdorf, Cole S., additional, Wolfe, Serena K., additional, Wei, Xiao X., additional, Silver, Rebecca, additional, Zhang, Zhenwei, additional, Morris, Michael J., additional, Bubley, Glenn, additional, Feng, Felix Y., additional, Scher, Howard I., additional, Rathkopf, Dana, additional, Dehm, Scott M., additional, Choueiri, Toni K., additional, Halabi, Susan, additional, Armstrong, Andrew J., additional, Wyatt, Alexander W., additional, Taplin, Mary-Ellen, additional, Zhao, Shuang G., additional, and Lang, Joshua M., additional

Published
2021
Full Text
View/download PDF

46. Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance

Author

McKay, Rana R., Kwak, Lucia, Crowdis, Jett P., Sperger, Jamie M., Zhao, Shuang G., Xie, Wanling, Werner, Lillian, Lis, Rosina, Zhang, Zhenwei, Wei, Xiao X., Lang, Joshua M., Van Allen, Eliezer M., Bhatt, Rupal S., Yu, Evan Y., Nelson, Peter S., Bubley, Glenn J., Montgomery, R. Bruce, and Taplin, Mary-Ellen

Subjects
Male, Prostatic Neoplasms, Castration-Resistant, Drug Resistance, Neoplasm, Benzamides, Nitriles, Phenylthiohydantoin, Humans, Prospective Studies, Neoplasm Metastasis, Article, Aged
Abstract

PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic castration resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase 2 multicenter study of enzalutamide in metastatic CRPC incorporating tissue and blood biomarkers to dissect mechanisms driving resistance. EXPERIMENTAL DESIGN: Eligible patients with metastatic CRPC underwent a baseline metastasis biopsy and then initiated enzalutamide 160 mg daily. A repeat metastasis biopsy was obtained at radiographic progression from the same site when possible. Blood for circulating tumor cell (CTC) analysis was collected at baseline and progression. The primary objective was to analyze mechanisms of resistance in serial biopsies. Whole exome sequencing was performed on tissue biopsies. CTC samples underwent RNA sequencing. RESULTS: 65 patients initiated treatment, of whom 22 (33.8%) had received prior abiraterone. Baseline biopsies were enriched for alterations in AR (mutations, amplifications) and tumor suppression genes (PTEN, RB1, and TP53) which were observed in 73.1% and 92.3% of baseline biopsies, respectively. Progression biopsies revealed increased AR amplifications (64.7% at progression versus 53.9% at baseline) and BRCA2 alterations (64.7% at progression versus 38.5% at baseline). Genomic analysis of baseline and progression CTC samples demonstrated increased AR splice variants, AR regulated-genes, and neuroendocrine markers at progression. CONCLUSIONS: Our results demonstrate that a large proportion of enzalutamide-treated patients have baseline and progression alterations in the AR pathway and tumor suppressor genes. We demonstrate an increased number of BRCA2 alterations post-enzalutamide highlighting importance of serial tumor sampling in CRPC.

Published
2021

47. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials

Author

McKay, Rana R., primary, Berchuck, Jacob, additional, Kwak, Lucia, additional, Xie, Wanling, additional, Silver, Rebecca, additional, Bubley, Glenn J., additional, Chang, Peter K., additional, Wagner, Andrew, additional, Zhang, Zhenwei, additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2021
Full Text
View/download PDF

48. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance

Author

McKay, Rana R., primary, Kwak, Lucia, additional, Crowdis, Jett P., additional, Sperger, Jamie M., additional, Zhao, Shuang G., additional, Xie, Wanling, additional, Werner, Lillian, additional, Lis, Rosina T., additional, Zhang, Zhenwei, additional, Wei, Xiao X., additional, Lang, Joshua M., additional, Van Allen, Eliezer M., additional, Bhatt, Rupal S., additional, Yu, Evan Y., additional, Nelson, Peter S., additional, Bubley, Glenn J., additional, Montgomery, R. Bruce, additional, and Taplin, Mary-Ellen, additional

Published
2021
Full Text
View/download PDF

49. Post-radical prostatectomy (RP) outcome for patients with high-risk prostate cancer treated with intense neoadjuvant hormone therapy (NHT): Results of a pooled analysis of contemporary clinical trials.

Author

McKay, Rana R., primary, Berchuck, Jacob E, additional, Kwak, Lucia, additional, Xie, Wanling, additional, Silver, Rebecca, additional, Bubley, Glenn, additional, Chang, Peter K., additional, Wagner, Andrew, additional, Zhang, Zhenwei, additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2021
Full Text
View/download PDF

50. Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.

Author

Choudhury, Atish Dipankar, primary, Kwak, Lucia, additional, Cheung, Alexander, additional, Tripathi, Abhishek, additional, Pace, Amanda Fredericks, additional, Van Allen, Eliezer Mendel, additional, Kilbridge, Kerry L., additional, Wei, Xiao X., additional, McGregor, Bradley Alexander, additional, Pomerantz, Mark, additional, Sweeney, Christopher, additional, Taplin, Mary-Ellen, additional, Jacene, Heather, additional, Bubley, Glenn, additional, Harshman, Lauren C, additional, Fong, Lawrence, additional, and Bhatt, Rupal Satish, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results